Work together to create a higher standard for the GTP supply chain in the field of life and health
Beijing, April 23, 2021-Saisheng Pharmaceutical Holdings Co., Ltd. (“Saisheng Pharmaceutical” or the “Company”, together with its subsidiaries, collectively referred to as the “Group”, stock code: 6600.HK) and SF Pharmaceutical formally announced Starting a strategic cooperation on April 22, 2021, SF Pharmaceutical became a certified GTP supply chain service provider of Saisheng Pharmaceutical. The two parties will give full play to their respective advantages – relying on Saisheng Pharmaceutical’s professional and deep cultivation in the field of life and health and SF Pharmaceutical’s successful practice in the integrated digital supply chain and innovative operation model, to work together to create a more efficient life and health enterprise to C-end patient users Provide professional, safe, and traceable end-to-end services to build a higher standard for China’s GTP supply chain in the field of life and health.
Mr. Zhao Hong, President and CEO of Saisheng Pharmaceutical, and Ms. Zhou Shun, General Manager of SF Pharmaceutical, signed a strategic cooperation agreement The signing ceremony of the strategic cooperation agreement was held in Beijing. Mr. Li Zhenfu, Chairman of Saisheng Pharmaceutical, Chairman and CEO of Telford Capital, Mr. Lu Jun, Chairman of SF Pharmaceuticals, Mr. Zhao Hong, President and CEO of Saisheng Pharmaceuticals, and Ms. Zhou Shun, General Manager of SF Pharmaceuticals, etc. Leadership representatives attended the ceremony and participated in the grand meeting. Group photo of Saisheng Pharmaceutical and senior leaders of SF Pharmaceutical At the signing ceremony, Mr. Zhao Hong, President and CEO of Saisheng Pharmaceutical, and Ms. Zhou Shun, General Manager of SF Pharmaceutical, successively discussed the overall plan for strategic cooperation between the two parties and the innovative Go-To-Patient (“GTP”) business model of Saisheng Pharmaceutical And SF’s medical service information visualization innovative business model was shared and exchanged. Saisheng Pharmaceutical’s GTP platform expands the sales channels of prescription drugs from hospitals to Direct-To-Patient (“DTP”) pharmacies, increasing the availability of prescription drugs to patients. Both parties agree that with SF Pharmaceuticals’ ability to adapt and respond to the supply chain in the life and health field, as well as its digital strength in manpower, production capacity and operations, this service provider certification and strategic cooperation symbolizes the establishment of GTP supply chain service standards in the life and health field. It will further deepen and develop the GTP model of Saisheng Pharmaceutical, broaden the coverage of the patient population, and improve the efficiency of patient service and the guarantee of product quality. The implementation and implementation of the GTP supply chain service standard in the commercial circulation will also promote the pharmaceutical supply chain model to realize the complementary roles of business flow and third-party logistics, and create more efficient forms of service for patients and enterprises. The two parties are confident that through this cooperation, we can achieve the end-to-end logistics model that can reach C directly, realize the nearest warehouse delivery, and improve the efficiency of the supply chain; full-process data service, obtain the most realistic flow data, and rationally manage existing customers and incremental customers; Manage and support targeted business flow channels and strengthen the orderly management of pharmaceutical companies to business flow companies; full-process professional temperature and humidity protection and information traceability, so that patients can obtain safe drug services. Mr. Li Zhenfu, Chairman of Saisheng Pharmaceutical, Chairman and CEO of Telford Capital, said at the signing ceremony: “As an international biopharmaceutical company with an integrated platform for product development and commercialization, Saisheng Pharmaceutical has been deeply involved in China for more than 20 years. Since its establishment, Saisheng Pharmaceutical has always taken the health of patients as its own responsibility, adhered to the culture of “strict compliance and high performance”, and provided patients with original high-quality products that meet international standards. Whether it is the core own product Ridaxian (thymus method) New original research drugs), or 8 other products under development, all have a huge market in the field of oncology and anti-infectives and the prospect of continuous increase in volume. And SF Pharmaceutical is a leader in third-party services in the field of life and health in China[1], Especially in the field of pharmaceutical cold chain products, has outstanding omni-channel supply chain capabilities. Through this service certification of SF’s supply chain and the opportunity of strategic cooperation, we will continue to expand the GTP model and better provide patients with professional, safe and reliable medical and health services. ” Mr. Lu Jun, Chairman of SF Pharmaceuticals, said in a speech: “We are very honored to be certified by Saisheng Pharmaceuticals, and we are full of confidence in this strategic cooperation. SF Pharmaceuticals has obtained the certification of pharmaceutical business quality management standards and modern pharmaceutical tripartite logistics qualifications. Personnel, quality system, operating standards, system traceability, etc. are in line with GSP standards[2]. We hope that based on our global service chassis and the medical warehouse network covered by the whole network, we can realize the innovative solution of “one stock, one network, one-stop” for Saisheng Pharmaceutical, and empower it in the field of life and health. Innovate business models and outstanding brand advantages to form an efficient, controllable and cost-optimized service system. At the same time, this will also promote the upgrading and reengineering of China’s pharmaceutical supply chain: it will not only optimize circulation links and reduce circulation costs for industrial enterprises and commercial circulation enterprises, but also bring more efficiency, higher quality and better quality to end patient users. Preferential medical services are of far-reaching significance in achieving a win-win ecosystem for life and health. ” Value first, mutual empowerment and common improvement. Saisheng Pharmaceutical Co., Ltd. and SF Pharmaceutical Co., Ltd. will work together to accelerate the implementation of high-quality innovative drugs, jointly develop digital innovation and industrial iteration, and achieve cooperation and strategic upgrades at a more end and three-dimensional level, and provide patients with international quality The medical products and services in the industry have given more new possibilities to the industry ecology, and through each other’s important influence in the industry, the service level of the entire life and health supply chain will be pushed to a new level. About Saisheng Pharmaceutical Holdings Limited Saisheng Pharmaceutical Holdings Co., Ltd. (listed on the Hong Kong Stock Exchange, stock code 6600) is a biopharmaceutical company with an integrated platform for product development and commercialization, strategically focusing on some of China’s larger and rapidly growing medical needs that have not been met The field of treatment includes oncology and severe infections. Relying on the product development and commercialization strength of Saisheng Pharmaceutical, the company has established a good track record in the development and commercialization of balanced and high-quality listed products in key therapeutic areas and the development and commercialization of products under research with better potential. For more information about Saisheng Pharmaceutical, please visit: About SF Pharmaceutical Supply Chain Holdings Co., Ltd. Shanghai SF Pharmaceutical Supply Chain Holdings Co., Ltd. is a wholly-owned subsidiary of SF Group (a company listed on the Shenzhen Stock Exchange, stock code 002352). Relying on SF Group’s advanced experience in supply chain service management, optimized adaptation and rapid response capabilities, it is committed to serving pharmaceutical manufacturers , Distribution companies, vaccine manufacturers, disease control centers at all levels, hospitals and chain pharmacies and other life and health industries provide third-party services of “C-end direct, cold chain guarantee, efficient warehouse distribution, full visibility, safety and reliability”, Help end users obtain better, safer, more efficient and more accessible medical services.
You must log in to post a comment.